Table 2 Analysis of differences in the composition of clinical factors in the training and validation groups.
Characteristic | Training group | Validation group | Valuea (χ2/Z) | P |
|---|---|---|---|---|
Total | 266 | 266 | ||
Age, median (IQR) | 59 (51, 69) | 62 (52, 71) | 38,523.5 | 0.076 |
Gender, n (%) | 0.82 | 0.364 | ||
Female | 88 (16.5%) | 99 (18.6%) | ||
Male | 178 (33.5%) | 167 (31.4%) | ||
Grade, n (%) | 5.1 | 0.277 | ||
G1 | 7 (1.3%) | 7 (1.3%) | ||
G2 | 104 (19.5%) | 124 (23.3%) | ||
G3 | 115 (21.6%) | 91 (17.1%) | ||
G4 | 37 (7%) | 39 (7.3%) | ||
Unknow | 3 (0.6%) | 5 (0.9%) | ||
Stage, n (%) | 2.61 | 0.625 | ||
Stage I | 134 (25.2%) | 132 (24.8%) | ||
Stage II | 24 (4.5%) | 33 (6.2%) | ||
Stage III | 64 (12%) | 60 (11.3%) | ||
Stage IV | 43 (8.1%) | 41 (7.7%) | ||
Unknow | 1 (0.2%) | 0 (0%) | ||
T, n (%) | 3.64 | 0.303 | ||
T1 | 137 (25.8%) | 135 (25.4%) | ||
T2 | 28 (5.3%) | 41 (7.7%) | ||
T3 | 94 (17.7%) | 86 (16.2%) | ||
T4 | 7 (1.3%) | 4 (0.8%) | ||
N, n (%) | 0.5 | 0.779 | ||
N0 | 116 (21.8%) | 124 (23.3%) | ||
N1 | 8 (1.5%) | 8 (1.5%) | ||
Unknow | 142 (26.7%) | 134 (25.2%) | ||
M, n (%) | 0.24 | 0.886 | ||
M0 | 210 (39.5%) | 211 (39.7%) | ||
M1 | 41 (7.7%) | 38 (7.1%) | ||
Unknow | 15 (2.8%) | 17 (3.2%) |
